Nasdaq:AUPH
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals is a US-based biopharmaceutical firm specializing in rare disease therapeutics with a recent transition to net income generation.
Key Metrics
Investment Thesis
Bull Case
Aurinia presents a compelling opportunity for investors seeking exposure to the high-growth rare disease sector with a company that has recently achieved profitability. The strong cash flow generation of over $135 million suggests a mature business model capable of funding further R&D without immediate dilution, while the revenue growth from 2022 to 2025 shows consistent market expansion.
Bear Case
Despite recent profitability, the company's total liabilities exceed $170 million against total assets of $751.6 million, requiring vigilance regarding debt servicing and liquidity management. Heavy reliance on R&D spending and the inherent volatility of clinical trial outcomes remain primary risks that could impact future earnings if key pipeline candidates fail.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (AUPH) is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare genetic diseases, primarily operating in the United States market. The company leverages its proprietary technology platform to advance multiple pipeline candidates targeting unmet medical needs. Key revenue drivers currently stem from licensing agreements and commercialization of approved assets that have transitioned into profitability.
Analysis
Management Discussion
The company demonstrated a remarkable operational turnaround, shifting from a net loss of $78 million in 2023 to a robust net profit of $287.2 million in the most recent year. This financial improvement was driven by significant growth in operating cash flow of $135.7 million and a total revenue increase to $283.1M, indicating successful commercialization or licensing execution.
Industry Overview
The biopharmaceutical industry is experiencing a surge in investment toward orphan drug development, driven by favorable regulatory incentives such as tax credits and extended patent exclusivity periods. This sector offers high margins but carries elevated technical and commercial risk, particularly for companies targeting small patient populations with specialized therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $134.0M | $175.5M | $235.1M | $283.1M |
| Cost of Revenue | $5.7M | $14.1M | $28.2M | $32.7M |
| Gross Profit | $128.4M | $161.4M | $206.9M | $250.4M |
| Operating Expenses | $239.8M | $253.1M | $239.8M | $178.1M |
| Operating Income | $-111.5M | $-91.7M | $-4.7M | $104.9M |
| R&D | $45.0M | $49.6M | $20.8M | $32.5M |
| G&A | $196.4M | $195.0M | $172.0M | $101.8M |
| Stock-Based Comp | $32.3M | $45.3M | $31.6M | $14.7M |
| D&A | $2.7M | $11.6M | $19.4M | $19.4M |
| Depreciation | $629.0K | $606.0K | $600.0K | $600.0K |
| Amortization | $2.1M | $1.7M | $900.0K | $800.0K |
| Other OpEx | $-1.5M | $8.4M | $47.0M | $43.8M |
| Non-Operating Income | $5.1M | $14.2M | $12.1M | $9.2M |
| Interest Expense | — | $2.8M | — | — |
| Interest Income | — | — | $17.0M | $13.6M |
| Pre-Tax Income | $-106.4M | $-77.5M | $7.4M | $114.2M |
| Income Tax | $1.8M | $551.0K | $1.7M | $-173.0M |
| Continuing Ops | $-108.2M | $-78.0M | $5.8M | $287.2M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-108.2M | $-78.0M | $5.8M | $287.2M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-108.2M | $-78.0M | $5.8M | $287.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $442.5M | $424.8M | $446.6M | $492.0M |
| Cash & Equivalents | $94.1M | $48.8M | $83.4M | $80.2M |
| Inventory | $24.8M | $39.7M | $39.2M | $45.7M |
| Other Current Assets | $323.7M | $336.3M | $324.0M | $366.1M |
| Long-Term Assets | $28.3M | $123.3M | $104.0M | $259.6M |
| PP&E (Net) | $3.6M | $3.4M | $2.7M | $2.1M |
| Operating Leases | $4.9M | $4.5M | $4.1M | $3.6M |
| Other LT Assets | $19.8M | $115.4M | $97.2M | $253.9M |
| Total Assets | $470.9M | $548.1M | $550.6M | $751.6M |
| Current Liabilities | $46.1M | $77.2M | $97.8M | $93.7M |
| Accounts Payable | — | — | $5.2M | $3.3M |
| Current Leases | $936.0K | $989.0K | $1.0M | $1.1M |
| Deferred Revenue | $3.1M | $4.8M | $11.0M | $3.7M |
| Other Current Liab | $42.0M | $71.4M | $15.6M | $19.0M |
| Long-Term Liabilities | $19.3M | $92.9M | $75.4M | $76.5M |
| LT Operating Leases | $7.2M | $6.5M | $5.7M | $4.9M |
| Other LT Liab | $12.2M | $86.4M | $69.7M | $59.0M |
| Total Liabilities | $65.4M | $170.1M | $173.2M | $170.3M |
| Shareholders' Equity | $405.4M | $378.0M | $377.5M | $581.3M |
| Retained Earnings | $-864.3M | $-942.3M | $-936.6M | $-649.4M |
| AOCI | $-1.1M | $-730.0K | $-647.0K | $-599.0K |
| Total L&E | $470.9M | $548.1M | $550.6M | $751.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-108.2M | $-78.0M | $5.8M | $287.2M |
| Non-Cash Adjustments | $15.2M | $6.0M | $5.6M | $-153.0M |
| Working Capital Changes | $13.5M | $38.6M | $33.0M | $1.5M |
| Cash from Operations | $-79.5M | $-33.5M | $44.4M | $135.7M |
| Cash from Investing | $-60.6M | $-6.7M | $39.3M | $-32.8M |
| Share Buybacks | — | — | $40.2M | $98.2M |
| Cash from Financing | $2.4M | $-5.1M | $-49.1M | $-106.1M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-137.7M | $-45.3M | $34.6M | $-3.2M |
| Beginning Cash | $231.9M | $94.2M | $48.9M | $83.4M |
| Ending Cash | $94.2M | $48.9M | $83.4M | $80.2M |
Frequently Asked Questions
How does Aurinia Pharmaceuticals Inc. make money?
Revenue is derived primarily from product sales and royalties associated with approved therapies for rare genetic conditions, supplemented by milestone payments and licensing fees from strategic academic or corporate partnerships. Operating expenses are dominated by research and development activities aimed at advancing late-stage clinical candidates.
What are the main risks for AUPH?
As a clinical-stage biopharmaceutical firm, the company faces significant regulatory risk regarding FDA approval timelines and efficacy data requirements for its pipeline assets. Revenue concentration in specific indications exposes the business to potential market access hurdles or reimbursement constraints within the US healthcare system. The substantial cash burn relative to current cash reserves necessitates careful capital allocation to avoid liquidity constraints before future milestones are reached.
What is AUPH's competitive advantage?
The company possesses a specialized technology platform capable of identifying and developing novel mechanisms of action specifically for orphan diseases with limited competition. Aurinia benefits from strong intellectual property protection surrounding its proprietary drug candidates, creating high barriers to entry for generic competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.